April 2024 Content Release Copied

04/25/20242024 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

AJCC Version 8 Staging

This release contains updated TNM values, Staging Groups, and Template functionality to align with AJCC version 8 conditions for:

  • Lymphoma, Non-Hodgkin (NHL), Primary Cutaneous Lymphoma, Mycosis Fungoides/Sezary Syndrome

Users will see updated values and descriptions for Tumor Type (T), Node (N), Metastasis (M), and Peripheral Blood Involvement (B) documentation points for Lymphoma, Non-Hodgkin (NHL), Primary Cutaneous Lymphoma, Mycosis Fungoides/Sezary Syndrome.

The following values are no longer available:

  • T1, T2, TX
  • N1, N2
  • M0, M1
  • B0, B1

The following documentation points now have updated descriptions:

  • N1a, N1b, N2a, N2b
  • cM0, cM1, pM1
  • B0a, B0b, B1a, B1b, B2

The staging calculator will display updated Stage values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Tumor Type Node Metastasis Blood Stage
T1 N0 M0 B0,1 IA
T2 N0 M0 B0,1 IB
T1,2 N1,2 M0 B0,1 IIA
T3 N0-2 M0 B0,1 IIB
T4 N0-2 M0 B0 IIIA
T4 N0-2 M0 B1 IIIB
T1-4 N0-2 M0 B2 IVA1
T1-4 N3 M0 B0-2 IVA2
T1-4 N0-3 M1 B0-2 IVB

Problem Groups

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

FOLR1 (Folate receptor alpha) expression is now available for Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer with the following documentation points:

  • Positive (>/=75%)
  • Negative (<75%)
  • Unknown

Updates

Problem Malignant tumor of female genital organ (disorder) was added to Problem Group Solid Tumors (Parent) (excluding HL/NHL/Solid Other) to support documentation of TMB (Tumor mutational burden).

Melanoma, Uvea, Ciliary Body/Choroid has been assigned a pathway (PW) designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping.

The following problems now have PW to the left of the problem in the search results:

  • Malignant melanoma of ciliary body (disorder)
  • Malignant melanoma of choroid (disorder)
  • Ring melanoma of ciliary body (disorder)
  • Malignant melanoma of uveal tract (disorder)
  • Malignant melanoma of left choroid (disorder)
  • Malignant melanoma of right choroid (disorder)

Problems

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Please see APPENDIX A for a complete summary of changes.

Procedures

Additions

New items are available for documentation in Procedures and appear in the Charge Capture Report (CCR).

  • Colposcopy of cervix including upper/adjacent vagina + biopsy(s) of cervix + ECC mapped to 57454
  • Colposcopy of cervix including upper/adjacent vagina + biopsy(s) of cervix mapped to 57544
  • ECC (not as part of D&C) (57505) mapped to 57505

Lab Analytes & Panels

Additions and Updates

  • -5/5q- by FISH
  • -7/7q- by FISH
  • +8 by FISH
  • 20q12 by FISH
  • Alpha globin gene released by
  • Alpha globin gene result summary
  • Alpha globin gene specimen
  • ANA additional pattern titer
  • Anti-SAE1 Ab, IgG, units
  • DRVVT complete panel
  • Factor 12 assay panel
  • Factor II assay panel
  • Factor X assay panel
  • Factor X, %
  • Factor XI assay panel
  • Factor XII assay, %
  • Folate, RBC, ng/mL
  • H. pylori Ab, IgG, U
  • Herpes simplex virus II specific Ab, IgG, AI
  • High risk HPV with genotype 16,18 panel
  • Histoplasma antigen, urine interpretation
  • Histoplasma antigen, urine specimen
  • Histoplasma antigen, urine, ng/ml
  • HLA-A 02:01
  • HPV mRNA E6/E7, rectal
  • HPV, other HR types
  • IgH by NGS
  • IgH gene rearrangement by NGS panel
  • Immunofixation, isatuximab-specific, serum panel
  • KIT D816V digital PCR, systemic mastocytosis
  • Lymphoma immunohisto. analysis
  • Lymphoma immunohisto. analysis panel
  • MAG antibody, IGM panel
  • MAG antibody, IGM, titer
  • MPL EXON 10 mutation detection, V panel
  • Myeloid disorder immunohisto.
  • Myeloid disorder immunohisto. panel
  • NeoGenomics panel
  • Neutrophil associated Ab clinical relevance
  • Neutrophil associated Ab electronic signature
  • Neutrophil associated Ab methodology
  • Neutrophil associated Ab reference
  • Neutrophil, smear, urine
  • Onkosight advanced plasma cell myeloma NGS comment
  • Onkosight advanced plasma cell myeloma NGS detailed genetic interpretation 1
  • OnkoSight advanced plasma cell myeloma NGS panel
  • Onkosight advanced plasma cell myeloma NGS technical summary
  • Onkosight NGS ABL1 sequencing
  • Onkosight NGS ABL1 sequencing interpretation
  • Onkosight NGS ABL1 sequencing methods
  • Onkosight NGS ABL1 sequencing panel
  • Onkosight NGS ABL1 sequencing references
  • Onkosight NGS ABL1 sequencing report footer
  • P53 by FISH panel
  • Parvovirus B19 PCR source
  • PEth 16:0/18:1 (POPEth) by LC MS/MS, ng/mL
  • PEth 16:0/18:2 (PLPEth) by LC MS/MS, ng/mL
  • PEth interpretation
  • Phosphatidylethanol (PEth) confirmation, blood panel
  • siParadigm panel
  • SPEP/IFE interpretation
  • T-cell gene rearrangement, PCR diagnosis
  • T-cell gene rearrangement, PCR signing pathologist
  • Thinprep pap smear panel
  • Wound fungus culture
  • Wound fungus culture panel
  • Wound, aerobic culture
  • Wound, aerobic culture panel
  • Wound, anaerobic culture
  • Wound, anaerobic culture panel

Medications

Additions

  • AO-252 invest Oral
  • JS001/TAB001 invest IV
  • JS004/TAB004 invest IV
  • M4076 invest Oral
  • PC14586 invest Oral
  • PF-07329640 invest IV
  • RMC-6291 invest Oral
  • Tifcemalimab invest (JS004/TAB004 invest IV)
  • Toripalimab invest (JS001/TAB001 invest IV)

Updates

Medication Update
AB801 invest Oral New Form available: 40 mg tablet
M1774 invest Oral New Form available: 30 mg tablet
Pemetrexed IV New Rounding Rule available: 100 mg

New Maximum Single Dose (flat) available: 1,250 mg

New Quick Sig Picks available:

  • Default Sig: Pemetrexed 500 mg/m2 intravenously Piggyback once; administer over 10 minutes
  • Pemetrexed 500 mg/m2 intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL. NOTE: This product is equivalent to Alimta
  • Pemetrexed 500 mg/m2 intravenously Piggyback once; administer over 10 minutes; Dilute with NS to a total volume of 100 mL. NOTE: This product is equivalent to Pemfexy
  • Pemetrexed 500 mg/m2 intravenously Piggyback once; administer over 10 minutes; Use empty IV bag. Do not further dilute. NOTE: This product is equivalent to Pemrydi RTU
PF-06801591 invest IV New Alias available: Sasanlimab invest
PF-06801591 invest Subcutaneous New Form available: 150 mg/mL (2 mL) pre-filled syringe
Sasanlimab invest Subcutaneous New Medication Term available: PF-06801591 invest Subcutaneous

Regimen Library

Additions

Regimen Name Diagnosis
Capecitabine D1-14 + Trastuzumab IV Q21D (Esophageal, Gastric) Gastric Cancer; Esophageal Cancer (Parent)
Cyclophosphamide (60 mg/kg) D1-2 + Fludarabine (25 mg/m2) D3-7 (TIL Therapy Lymphodepletion) Melanoma, Skin
Daratumumab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2) Multiple Myeloma (MM)
Gemcitabine D1,8 + Cisplatin Q21D (Uterine) Uterine Cancer (Parent)
Infliximab SQ D1,15 (Maintenance) Q28D Crohn’s Disease; Ulcerative Colitis
Lifileucel (Amtagvi TIL) fb IL-2 Off-Site Documentation Melanoma, Skin

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Anal Cancer (Parent)
  • Bile Duct Cancer (Parent)
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer (Parent)
  • Fallopian Tube Cancer
  • Gallbladder Cancer
  • Gastric Cancer
  • Head and Neck Cancer (Parent)
  • Hepatocellular Carcinoma (HCC)
  • Lung Cancer, Non-small Cell (SCLC)
  • Lung Cancer, Small Cell (NSCLC)
  • Lymphoma, Hodgkin (HL)
  • Malignant Mesothelioma
  • Malignant Pleural Mesothelioma
  • Melanoma, Ciliary Body/Choroid
  • Melanoma, Skin
  • Merkel Cell Carcinoma
  • Multiple Myeloma (MM)
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer, Carcinoid/Neuroendocrine
  • Rectal Cancer
  • Renal Cell Carcinoma (RCC)
  • Renal Pelvis and Ureter Cancer
  • Urethral Cancer
  • Uterine Cancer (Parent)

Renames

Previous Name New Name
Capecitabine D1-14 + Trastuzumab IV Q21D Capecitabine D1-14 + Trastuzumab IV Q21D (Breast)

Research

Updates

Updated Reference Information Updated Drug Service Order Information Other Changes
USOR 19062 X X
USOR 20336 X
USOR 21493 X
USOR 22101 X
USOR 22167 X X
USOR 22245 Now available:

  • USOR 22245 Part 1b NGM707 + Pembrolizumab Q21D
USOR 22249 X
USOR 23091 X

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
atidarsagene autotemcel IV J3590 per 6.6 x 10e6 CD34+ cells
immune globulin, gamma (IgG)-stwk IV J3590 per 500 mg
infliximab-dyyb Subcutaneous J3590 per 120 mg
Pemetrexed (pemrydi rtu) J9324 per 10 mg
Spesolimab-sbzo Subcutaneous J1747 per 1 mg
Sotatercept-csrk Subcutaneous J3590 per 45 mg

NDC to HCPCS Crosswalk

Additions

Medication (Brand) HCPCS Code NDC
Pemetrexed (pemrydi rtu) J9324 per 10 mg 70121245301
70121246101
Spesolimab-sbzo Subcutaneous J1747 per 1 mg 00597003510

Appendix A

Problem & Codes Summary

Additions

Problem ICD-10 Codes
Encounter for antineoplastic immunotherapy Z51.12 Encounter for antineoplastic immunotherapy
Long-term current use of aromatase inhibitor Z79.811 – Long term (current) use of aromatase inhibitors
Prostate cancer C61 – Malignant neoplasm of prostate